Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

July 29, 2019

Primary Completion Date

July 13, 2020

Study Completion Date

July 13, 2020

Conditions
Nonalcoholic Steatohepatitis
Interventions
DRUG

Semaglutide

Solution administered subcutaneously with pre-filled PDS290 pen-injector once weekly

DRUG

Firsocostat

Tablets administered orally once daily

DRUG

Cilofexor

Tablets administered orally once daily

Trial Locations (18)

11030

Northwell Health, Manhasset

28078

Gastro One, Huntersville

30060

Gastrointestinal Specialists of Georgia, Marietta

37211

Quality Medical Research, PLLC, Nashville

38138

Gastro One, Germantown

75203

The Liver Institute at Methodist Dallas Medical Center, Dallas

76012

Texas Clinical Research Institute, Arlington

78215

American Research Corporation, San Antonio

85224

Institute for Liver Health - Arizona Liver Health, Chandler

89109

Jubilee Clinical Research, Inc., Las Vegas

90036

Ruane Clinical Research Group, Inc, Los Angeles

90048

Cedars Sinai Medical Center, Los Angeles

92093

University of California San Diego (UCSD), La Jolla

92118

Southern California Research Centers, Coronado

92123

Medical Associates Research Group, San Diego

92377

Inland Empire Clinical Trials, LLC, Rialto

02215

Beth Israel Deaconess Medical Center, Boston

02905

University Gastroenterology, Providence

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Gilead Sciences

INDUSTRY